Macrophages expressing a fusion protein derived from bactericidal/permeability-increasing protein and IgG are resistant to endotoxin

Archives of Surgery

Volumn 131, Issue 11, 1996, Pages 1173-1178

  Dahlberg, Peter S ^a   Acton, Robert D ^a   Uknis, Marc E ^a   Klaerner, Hanz G ^a   Johnston, Jennifer W ^a   Levelle, Christopher D ^a   Gray, Beulah H ^b   Dunn, David L ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c University of Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CELL MEMBRANE PERMEABILITY; CONFERENCE PAPER; CROSS REACTION; GENETIC TRANSFECTION; GRAM NEGATIVE INFECTION; INFECTION RESISTANCE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECRETION; SUPERNATANT;

EID: 0029854969     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1996.01430230055010     Document Type: Conference Paper

References (14)

1. Dunn DL. Role of endotoxin and host cytokines in septic shock. Chest. 1991; 100(suppl):164S-168S.
2. Burd RS, Battafarano RJ, Cody CS, Farber MS, Ratz CA, Dunn DL. Antiendotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor a by two distinct mechanisms. Ann Surg. 1993;218:250-261.
3. The CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double blind, placebo-controlled trial. Ann Intern Med. 1994;121:1-5.
4. Warren HS, Amato SF, Fitting C, et al.Assessment of ability of murine and human antilipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993;177:89-97.
5. Evans TJ, Carpenter A, Moyes D, Martin R, Cohen J. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. J Infect Dis. 1995;171:153-160.
6. Battafarano RJ, Dahlberg PS, Ratz CA, et al. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor a secretion in vitro. Surgery. 1995;118:318-324.
7. Davis, L, Kuehl M, Battey J. Basic Methods in Molecular Biology. Norwalk, Conn; Appleton & Lange; 1994:733-738.
8. Kohn FR, Ammons WS, Horwitz A, et al. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. J Infect Dis. 1993;168:1307-1310.
9. Kelly CJ, Cech AC, Argenteanu M, et al. Role of bactericidal/permeability-increasing protein in the treatment of gram-negative pneumonia. Surgery. 1993; 114,140-146.
10. Bauer RJ, White ML, Wedel N, et al. A phase I safety and pharmacokinetic study of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock. 1996;5:91-96.
11. Hoess A, Watson S, Siber GR, Liddington R. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab: Limulus anti-LPS factor, at 1.5 resolution. EMBO J. 1993;12:3351-3356.
12. Gray BH, Haseman JR. Bactericidal activity of synthetic peptides based on the structure of the 55-kilodalton bactericidal protein from human neutrophils. Infect Immun. 1994;62:2732-2739.
13. Dahlberg PS, Acton RD, Battafarano RJ, et al. A novel endotoxin antagonist attenuates tumor necrosis factor a secretion. J Surg Res. In press.
14. Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA. 1995;274:338-345.